E-LIB Suche - Ergebnisse für: Mascarenhas, John O.

1

Erratum to: Retrospective analysis of pacritinib in patient..:

Verstovsek, Srdan ; Mesa, Ruben ; Talpaz, Moshe...
Haematologica. 109 (2024) 4 - p. 3010 , 2024

Link: https://doi.org/10.3324/..

2

Management of isocitrate dehydrogenase 1/2 mutated acute my..:

Fruchtman, Harry ; Avigan, Zachary M. ; Waksal, Julian A...
Leukemia. 38 (2024) 5 - p. 927-935 , 2024

Link: https://doi.org/10.1038/..

3

Treating accelerated and blast phase myeloproliferative neo..:

Ajufo, Helen O. ; Waksal, Julian A. ; Mascarenhas, John O..
Therapeutic Advances in Hematology. 14 (2023) - p. , 2023

Link: https://doi.org/10.1177/..

4

Telomerase-targeted therapies in myeloid malignancies:

Waksal, Julian A. ; Bruedigam, Claudia ; Komrokji, Rami S...
Blood Advances. 7 (2023) 16 - p. 4302-4314 , 2023

Link: https://doi.org/10.1182/..

5

The clinical dilemma of JAK inhibitor failure in myelofibro..:

Mascarenhas, John O. ; Verstovsek, Srdan
Cancer. 128 (2022) 14 - p. 2717-2727 , 2022

Link: https://doi.org/10.1002/..

6

Retrospective analysis of pacritinib in patients with myelo..:

Verstovsek, Srdan ; Mesa, Ruben ; Talpaz, Moshe...
Haematologica. 107 (2021) 7 - p. 1599-1607 , 2021

Link: https://doi.org/10.3324/..

7

JAKs to STATs: A tantalizing therapeutic target in acute my..:

Venugopal, Sangeetha ; Bar-Natan, Michal ; Mascarenhas, John O.
Blood Reviews. 40 (2020) - p. 100634 , 2020

Link: https://doi.org/10.1016/..

8

Determining the recommended dose of pacritinib: results fro..:

Gerds, Aaron T. ; Savona, Michael R. ; Scott, Bart L....
Blood Advances. 4 (2020) 22 - p. 5825-5835 , 2020

Link: https://doi.org/10.1182/..

9

Phase 2 study of ruxolitinib and decitabine in patients wit..:

Mascarenhas, John O. ; Rampal, Raajit K. ; Kosiorek, Heidi E....
Blood Advances. 4 (2020) 20 - p. 5246-5256 , 2020

Link: https://doi.org/10.1182/..

10

Metabolic Effects of JAK1/2 Inhibition in Patients with Mye..:

Sapre, Manali ; Tremblay, Douglas ; Wilck, Eric...
Scientific Reports. 9 (2019) 1 - p. , 2019

Link: https://doi.org/10.1038/..

11

Impact of High-Molecular-Risk Mutations on Transplantation ..:

Tamari, Roni ; Rapaport, Franck ; Zhang, Nan...
Biology of Blood and Marrow Transplantation. 25 (2019) 6 - p. 1142-1151 , 2019

Link: https://doi.org/10.1016/..

12

The Implications of Liver Biopsy Results in Patients with M..:

Tremblay, Douglas ; Putra, Juan ; Vogel, Alexander...
Case Reports in Hematology. 2019 (2019) - p. 1-3 , 2019

Link: https://doi.org/10.1155/..

13

Ruxolitinib Therapy Followed by Reduced-Intensity Condition..:

Gupta, Vikas ; Kosiorek, Heidi E. ; Mead, Adam...
Biology of Blood and Marrow Transplantation. 25 (2019) 2 - p. 256-264 , 2019

Link: https://doi.org/10.1016/..

14

Inhibition of interleukin-1 receptor-associated kinase 1 (I..:

Singer, Jack W. ; Fleischman, Angela ; Al-Fayoumi, Suliman...
Oncotarget. 9 (2018) 70 - p. 33416-33439 , 2018

Link: https://doi.org/10.18632..

15

Safety and efficacy of combined ruxolitinib and decitabine ..:

Rampal, Raajit K. ; Mascarenhas, John O. ; Kosiorek, Heidi E....
Blood Advances. 2 (2018) 24 - p. 3572-3580 , 2018

Link: https://doi.org/10.1182/..